Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

BCL-2 Hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer

Stone, A., Cowley, M. J., Valdes-Mora, F., McCloy, R. A., Sergio, C. M., Gallego-Ortega, D., Caldon, C. E., Ormandy, C. J., Biankin, A. V., Gee, Julia Margaret Wendy, Nicholson, Robert Ian, Print, C. G., Clark, S. J. and Musgrove, E. A. 2013. BCL-2 Hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. Molecular Cancer Therapeutics 12 (9) , pp. 1874-1885. 10.1158/1535-7163.MCT-13-0012

Full text not available from this repository.
Item Type: Article
Date Type: Publication
Status: Published
Schools: Pharmacy
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
Publisher: American Association for Cancer Research
ISSN: 1535-7163
Last Modified: 04 Jun 2017 06:14
URI: http://orca-mwe.cf.ac.uk/id/eprint/57625

Citation Data

Cited 17 times in Google Scholar. View in Google Scholar

Cited 33 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item